Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics : A Systematic Review and Network Meta-Analysis
© 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology..
OBJECTIVE: Anterior uveitis is a common extra-articular manifestation of axial spondyloarthritis (AxSpA). We set to evaluate the risk of anterior uveitis (AU) with biologics and synthetic disease-modifying drugs in AxSpA.
METHODS: We conducted a systematic review and meta-analysis to identify phase II/III double-blinded randomized controlled trials of anti-tumor necrosis factor (TNF) monoclonal antibodies (mAb), anti-interleukin-17 (anti-IL-17), and Janus kinase inhibitors (JAKi) in AxSpA. Patient-exposure years (PEY) were calculated using the per-protocol approach. Incidence rate (IR) of AU/100 person-years were calculated by treatment group using the random effects approach. Network meta-analysis (NMA) was used to estimate risk of AU in treatment groups, expressed as IR ratios (IRRs). Bias was assessed using the Cochrane Risk of Bias-2 tool.
RESULTS: Forty-four trials were included: 17 anti-TNF mAb (1,004 PEY), 9 etanercept (180 PEY), 13 anti-IL-17 (1,834 PEY), and 6 JAKi (331 PEY). The IR of AU were as follows for anti-TNF mAb: 4.1, 95% confidence interval (CI) 0-8.5; etanercept: 5.4, 95% CI 0-16.0; anti-IL-17: 2.8, 95% CI 1.6-4.1; JAKi: 1.5, 95% CI 0.0-3.0; and placebo: 10.8, 95% CI 7.4-14.1. In NMA, IRRs of treatments compared with placebo were as follows for anti-TNF mAb: 0.32, 95% CI 0.10-1.04; etanercept 0.42, 95% CI 0.08-2.38; anti-IL-17: 0.43, 95% CI 0.19-0.98; and JAKi: 0.32, 95% CI 0.06-1.67. Comparisons between anti-TNF mAb, anti-IL-17, and JAKi did not demonstrate any significant difference in AU risk. Using the surface under the cumulative ranking curve approach to rank AU risk, anti-TNF mAbs were associated with the lowest risk followed by JAKi, anti-IL-17, and etanercept. All treatments were ranked superior to placebo.
CONCLUSION: Anti-TNF mAbs, JAKi, and anti-IL-17 appear protective against AU events in individuals with AxSpA, with no significant differences in risk of AU between treatments.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
---|---|
Enthalten in: |
Arthritis & rheumatology (Hoboken, N.J.) - 76(2024), 5 vom: 20. Apr., Seite 704-714 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bechman, Katie [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 25.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/art.42788 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM366073664 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM366073664 | ||
003 | DE-627 | ||
005 | 20240426233456.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231227s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/art.42788 |2 doi | |
028 | 5 | 2 | |a pubmed24n1388.xml |
035 | |a (DE-627)NLM366073664 | ||
035 | |a (NLM)38116697 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bechman, Katie |e verfasserin |4 aut | |
245 | 1 | 0 | |a Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics |b A Systematic Review and Network Meta-Analysis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.04.2024 | ||
500 | |a Date Revised 25.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. | ||
520 | |a OBJECTIVE: Anterior uveitis is a common extra-articular manifestation of axial spondyloarthritis (AxSpA). We set to evaluate the risk of anterior uveitis (AU) with biologics and synthetic disease-modifying drugs in AxSpA | ||
520 | |a METHODS: We conducted a systematic review and meta-analysis to identify phase II/III double-blinded randomized controlled trials of anti-tumor necrosis factor (TNF) monoclonal antibodies (mAb), anti-interleukin-17 (anti-IL-17), and Janus kinase inhibitors (JAKi) in AxSpA. Patient-exposure years (PEY) were calculated using the per-protocol approach. Incidence rate (IR) of AU/100 person-years were calculated by treatment group using the random effects approach. Network meta-analysis (NMA) was used to estimate risk of AU in treatment groups, expressed as IR ratios (IRRs). Bias was assessed using the Cochrane Risk of Bias-2 tool | ||
520 | |a RESULTS: Forty-four trials were included: 17 anti-TNF mAb (1,004 PEY), 9 etanercept (180 PEY), 13 anti-IL-17 (1,834 PEY), and 6 JAKi (331 PEY). The IR of AU were as follows for anti-TNF mAb: 4.1, 95% confidence interval (CI) 0-8.5; etanercept: 5.4, 95% CI 0-16.0; anti-IL-17: 2.8, 95% CI 1.6-4.1; JAKi: 1.5, 95% CI 0.0-3.0; and placebo: 10.8, 95% CI 7.4-14.1. In NMA, IRRs of treatments compared with placebo were as follows for anti-TNF mAb: 0.32, 95% CI 0.10-1.04; etanercept 0.42, 95% CI 0.08-2.38; anti-IL-17: 0.43, 95% CI 0.19-0.98; and JAKi: 0.32, 95% CI 0.06-1.67. Comparisons between anti-TNF mAb, anti-IL-17, and JAKi did not demonstrate any significant difference in AU risk. Using the surface under the cumulative ranking curve approach to rank AU risk, anti-TNF mAbs were associated with the lowest risk followed by JAKi, anti-IL-17, and etanercept. All treatments were ranked superior to placebo | ||
520 | |a CONCLUSION: Anti-TNF mAbs, JAKi, and anti-IL-17 appear protective against AU events in individuals with AxSpA, with no significant differences in risk of AU between treatments | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Biological Products |2 NLM | |
650 | 7 | |a Antirheumatic Agents |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Interleukin-17 |2 NLM | |
650 | 7 | |a Etanercept |2 NLM | |
650 | 7 | |a OP401G7OJC |2 NLM | |
650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
700 | 1 | |a Yang, Zijing |e verfasserin |4 aut | |
700 | 1 | |a Adas, Maryam |e verfasserin |4 aut | |
700 | 1 | |a Nagra, Deepak |e verfasserin |4 aut | |
700 | 1 | |a S Uğuzlar, Ali |e verfasserin |4 aut | |
700 | 1 | |a Russell, Mark D |e verfasserin |4 aut | |
700 | 1 | |a Wilson, Nicky |e verfasserin |4 aut | |
700 | 1 | |a Steer, Sophia |e verfasserin |4 aut | |
700 | 1 | |a Norton, Sam |e verfasserin |4 aut | |
700 | 1 | |a Galloway, James |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Arthritis & rheumatology (Hoboken, N.J.) |d 2014 |g 76(2024), 5 vom: 20. Apr., Seite 704-714 |w (DE-627)NLM234543671 |x 2326-5205 |7 nnns |
773 | 1 | 8 | |g volume:76 |g year:2024 |g number:5 |g day:20 |g month:04 |g pages:704-714 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/art.42788 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 76 |j 2024 |e 5 |b 20 |c 04 |h 704-714 |